These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 1432700

  • 21. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
    Britzi M, Bialer M, Arcavi L, Shachbari A, Kapitulnik T, Soback S.
    Ther Drug Monit; 2000 Oct; 22(5):510-6. PubMed ID: 11034254
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Metabolic activity of dextromethorphan O-demethylation in healthy Japanese volunteers carrying duplicated CYP2D6 genes: duplicated allele of CYP2D6*10 does not increase CYP2D6 metabolic activity.
    Ishiguro A, Kubota T, Ishikawa H, Iga T.
    Clin Chim Acta; 2004 Jun; 344(1-2):201-4. PubMed ID: 15149890
    [Abstract] [Full Text] [Related]

  • 27. Polymorphism of dextromethorphan oxidation in Polish population.
    Skretkowicz J, Wojtczak A, Rychlik-Sych M.
    Acta Pol Pharm; 2008 Jun; 65(5):611-5. PubMed ID: 19051610
    [Abstract] [Full Text] [Related]

  • 28. [Cytochrome p450 IID6, its role in psychopharmacology].
    Lamard L, Pérault MC, Bouquet S, Guibert S.
    Ann Med Psychol (Paris); 1995 Feb; 153(2):140-3. PubMed ID: 7741408
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
    Jones DR, Gorski JC, Haehner BD, O'Mara EM, Hall SD.
    Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
    [Abstract] [Full Text] [Related]

  • 32. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.
    Turgeon J, Evans WE, Relling MV, Wilkinson GR, Roden DM.
    Br J Clin Pharmacol; 1991 Sep; 32(3):283-8. PubMed ID: 1685663
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
    Schadel M, Wu D, Otton SV, Kalow W, Sellers EM.
    J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs).
    Kuhlmann JB, Wensing G, Kuhlmann J.
    Int J Clin Pharmacol Ther; 2014 Feb; 52(2):143-50. PubMed ID: 24361088
    [Abstract] [Full Text] [Related]

  • 37. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
    McCune JS, Lindley C, Decker JL, Williamson KM, Meadowcroft AM, Graff D, Sawyer WT, Blough DK, Pieper JA.
    J Clin Pharmacol; 2001 Jul; 41(7):723-31. PubMed ID: 11452704
    [Abstract] [Full Text] [Related]

  • 38. Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy black American adult subjects.
    Marinac JS, Foxworth JW, Willsie SK.
    Ther Drug Monit; 1995 Apr; 17(2):120-4. PubMed ID: 7624898
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Investigation of terbinafine as a CYP2D6 inhibitor in vivo.
    Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL.
    Clin Pharmacol Ther; 1999 May; 65(5):465-72. PubMed ID: 10340911
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.